Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany

  • Olaf Ortmann
  • Ulrike Helbig
  • Julie Torode
  • Stefan Schreck
  • Sakari Karjalainen
  • Manola Bettio
  • Ulrik Ringborg
  • Monika Klinkhammer-Schalke
  • Freddy Bray
  • For the participants of the ERTM
Review – Clinical Oncology
  • 21 Downloads

Abstract

Purpose

National Cancer Control Plans (NCCPs) often describe structural requirements for high quality cancer care. During the fourth European Roundtable Meeting (ERTM) participants shared learnings from their own national setting to formulate best practice in optimizing communication strategies between parties involved in clinical cancer registries, cancer centers and guideline groups.

Results

A decentralized model of data collection close to the patient and caregiver enhances timely completion and the quality of the data captured. Nevertheless, central coordination is necessary to define datasets, indicators, standard settings, education, training and quality control to maintain standards across the network. In particular, interaction of parties in cancer care network has to be established and maintained on a regular basis.

Conclusion

After establishing the structural requirements of cancer care networks, communication between the different components and parties is required to analyze outcome data, provide regular reporting to all and develop strategies for continuous improvement of quality across the network.

Keywords

Quality of cancer care Cancer center Cancer registry Guidelines 

Notes

Acknowledgements

List of all participants

Association of European Cancer Leagues: Prof. Dr. Sakari Karjalainen, President of the Association of European Cancer Leagues, Secretary General, Cancer Society Finland, Helsinki, Finland

European Commission: Manola Bettio, Group Leader, Directorate General Joint Research Centre, Ispra, Italy, Dr. Stefan Schreck, Head of the Health Programme and Chronic Diseases’ Unit of the Directorate General for Health and Food Safety (DG-SANTE), Luxembourg

France: Dr. Freddy Bray, Head of Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon

Slovenia: Prof. Dr. Tit Albreht, Head of the Centre for Health Care—National Institute of Public Health, Lubljana

Sweden: Prof. Dr. Ulrik Ringborg, Chairperson of the EUROCAN Platform, Director Cancer Center Karolinska, Stockholm

Switzerland/Global: Dr. Julie Torode, Deputy CEO, Advocacy and Networks Director, Union for International Cancer Control (UICC), Geneva

The Netherlands: Prof. Dr. Jan-Willem Coebergh, former Head of the Department of Public Health, Erasmus MC Rotterdam, Prof. Dr. Sabine Siesling, Dept. of Registration and Research, Comprehensive Cancer Care Centre of the Netherlands, Utrecht

United Kingdom: Prof. Dr. Henrik Møller, Head of Cancer Epidemiology, King’s College, London

Germany: Dr. Johannes Bruns, Secretary-General of the German Cancer Society, Berlin, Dr. Markus Follmann MPH MSc, Section Director Guidelines, German Cancer Society, Germany, Dr. Ulrike Helbig MBA, General Manager Section A, German Cancer Society, Berlin, Prof. Dr. Andreas Hochhaus, Board Member of the German Cancer Society, Director Dept. Haematology and Clinical Oncology, Director of the University Tumor Centre Jena, PD Dr. Monika Klinkhammer-Schalke, Director Tumor Centre Regensburg, Managing Board Member German Tumor Centres Work Group, Berlin, Dr. Christoph Kowalski, Research Coordination Certification, German Cancer Society, Berlin, Prof. Dr. Margarete Landenberger, Institute of Health and Nursing Science, Medical Faculty of Martin-Luther University Halle-Wittenberg, Halle (Saale), Prof. Dr. Florian Lordick, Board Member of the German Cancer Society, Director of the University Cancer Centre Leipzig (UCCL), Prof. Dr. Olaf Ortmann, Vice President of the German Cancer Society, Director Department Gynaecology and Obstetrics, University Medical Center Regensburg, Dr. Simone Wesselmann MBA, Section Director Certification, German Cancer Society, Berlin.

Author contributions

OO: manuscript writing, editing. UH: manuscript writing, editing. JT: manuscript writing, editing. SS: manuscript writing, editing. SK: manuscript writing, editing. MB: manuscript writing, editing. UR: manuscript writing, editing. MK: manuscript writing, editing. FB: manuscript writing, editing.

Compliance with ethical standards

Conflict of interest

Author U. Helbig M. D. declares that she has no conflict of interest. Author J. Torode declares that she has no conflict of interest. Author O. Ortmann M.D. declares that he has no conflict of interest. Author S. Schreck declares that he has no conflict of interest. Author S. Karjalainen declares that he has no conflict of interest. Author M. Bettio declares that she has no conflict of interest. Author U. Ringborg declares that he has no conflict of interest. Author M. Klinkhammer-Schalke declares that she has no conflict of interest. Author F. Bray declares that he has no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Cancer Control Joint Action. http://www.cancercontrol.eu/. Accessed 11 Jan 2018
  2. European C Patient coalition. http://www.ecpc.org. Accessed 11 Jan 2018
  3. Martin Moreno JM, Albrecht T, Rados Kruel S et al (2013) Boosting Innovation and cooperation in European Cancer Control: key findings from the European Partnership for Action Against Cancer (EPAAC) National Institution of Public Health of the Republic of Slovenia and World Health Organization. http://www.epaac.eu/. Accessed 11 Jan 2018
  4. Ortmann O, Helbig U, Torode J (2015) Improving cancer care in Europe: which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin. J Cancer Res Clin Oncol 142(1):1–4.  https://doi.org/10.1007/s00432-014-1906-x (Epub 2015 Feb 3) CrossRefPubMedGoogle Scholar
  5. Ortmann O, Torode J, Helbig U (2016) Improving structural development in oncology: transformation of theoretical health care standards and knowledge into a practical approach—2nd European Roundtable Meeting (ERTM), May 8, 2015, Berlin, Germany. J Cancer Res Clin Oncol 142(4):807–811.  https://doi.org/10.1007/s00432-015-2052-9 (Epub 2015 Oct 19) CrossRefPubMedGoogle Scholar
  6. Ortmann O, Helbig U, Rösler W (2017) Current developments in cancer care: including the patients’ perspective-3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany. J Cancer Res Clin Oncol 143(4):673–676.  https://doi.org/10.1007/s00432-016-2320-3 (Epub 2016 Dec 17) CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Olaf Ortmann
    • 1
    • 3
  • Ulrike Helbig
    • 1
  • Julie Torode
    • 2
  • Stefan Schreck
    • 4
  • Sakari Karjalainen
    • 5
    • 6
  • Manola Bettio
    • 7
  • Ulrik Ringborg
    • 8
    • 9
  • Monika Klinkhammer-Schalke
    • 10
    • 11
  • Freddy Bray
    • 12
  • For the participants of the ERTM
  1. 1.German Cancer SocietyBerlinGermany
  2. 2.Union for International Cancer Control (UICC)GenevaSwitzerland
  3. 3.Department of Gynecology and ObstetricsUniversity Medical Center RegensburgRegensburgGermany
  4. 4.Health programme and chronic diseases Directorate-General for Health and Food SafetyLuxembourg CityLuxembourg
  5. 5.European Cancer LeaguesBrusselsBelgium
  6. 6.Cancer Society FinlandHelsinkiFinland
  7. 7.European Commission, Joint Research CentreIspraItaly
  8. 8.EUROCAN PlatformStockholmSweden
  9. 9.Cancer Center KarolinskaStockholmSweden
  10. 10.German Tumor Centres Work GroupBerlinGermany
  11. 11.Tumor Centre RegensburgRegensburgGermany
  12. 12.International Agency for Research on CancerLyonFrance

Personalised recommendations